GLOBAL MONOCLONAL ANTIBODY-BASED PROSTATE CANCER IMMUNOTHERAPY MARKET SIZE (2024 -2030)

The estimation for the Global Monoclonal Antibody-Based Prostate Cancer Immunotherapy Market stood at USD 88.41 Billion in 2023, with a projected value of USD 285.15 Billion by 2030. This growth reflects a CAGR of 18.21% during the forecast period spanning from 2024 to 2030.

In the realm of prostate cancer treatment, monoclonal antibodies play a crucial role in immunotherapy. This therapeutic approach employs engineered proteins capable of binding specifically to sites on or around prostate cancer cells, thereby hindering their activity, delivering cytotoxic agents, or eliciting an immune response. Targeting molecules such as PSMA, prostatic acid phosphatase, CTLA-4, PD-1, PD-L1, and B7-H3, monoclonal antibodies can be utilized independently or in combination with chemotherapy, radiation, or other immunotherapies. These monoclonal antibodies offer advantages such as precise targeting, extended serum half-life, and immune effector functions. Both presently available and forthcoming monoclonal antibody-based treatments hold the promise of significantly enhancing the quality of life for millions worldwide.

Global Monoclonal Antibody-Based Prostate Cancer Immunotherapy Market Drivers:

Monoclonal Antibodies Maintaining Dominance in the Global Immunotherapy Drug Market:

The global cancer immunotherapy market, categorized by various therapeutic modalities including cancer vaccines, immune checkpoint inhibitors, PD-1/PD-L1 inhibitors, CTLA-4 inhibitors, immune system modulators, monoclonal antibodies, and others, showcased a substantial market share for monoclonal antibodies in 2021. Among recommended immunotherapeutic drugs, monoclonal antibodies stand out prominently. Their efficacy as immunotherapeutic options was underscored when Amgen approved Blincyto (blinatumomab), a bispecific antibody targeting B-cell lymphoblastic leukemia. Monoclonal antibodies have emerged as the preferred treatment modality across a significant portion of the global healthcare market due to their affordability relative to alternative therapies. Ongoing research into conjugated, bispecific, and naked antigen-binding monoclonal antibodies has led to the discovery of new avenues in cancer treatment.

Increasing Incidence of Prostate Cancer, One of the Most Common Male Cancers Globally:

Prostate cancer, a malignancy that can affect the prostate gland within the male reproductive system, presents symptoms such as urinary issues, erectile dysfunction, hematuria, bone pain, among others. Factors influencing prostate cancer development include age, ethnicity, family history, genetic predisposition, lifestyle, and environmental exposures. The risk of prostate cancer escalates with age, predominantly impacting males over 50 years old. Additionally, specific genetic mutations or a familial history of prostate cancer can heighten the susceptibility to this disease. The rising incidence of prostate cancer underscores the urgent need for safe and effective therapies that can enhance patient survival and quality of life. Monoclonal antibody-based therapy stands out as a targeted strategy to address antigens or molecules expressed by prostate cancer cells or within their microenvironment, offering avenues to inhibit, poison, or activate the immune system against cancer cells.

Global Monoclonal Antibody-Based Prostate Cancer Immunotherapy Market Challenges:

Potential Side Effects and Immune-Related Toxicities of Monoclonal Antibody-Based Prostate Cancer Therapy:

Following the administration of monoclonal antibody-based therapy, adverse reactions such as infusion reactions, allergic responses, rash, fatigue, fever, nausea, diarrhea, and infections can occur. These adverse effects can be attributed to various mechanisms including anaphylaxis, anaphylactoid reactions, serum sickness, tumor lysis syndrome, and cytokine release syndrome. The severity of these side effects, ranging from mild to life-threatening, depends on factors such as the type, dosage, and schedule of monoclonal antibody-based therapy, as well as the patient's health profile and medical history. Immune-related toxicities can manifest as autoimmune diseases, inflammation, or organ damage when the immune system is either stimulated or suppressed by monoclonal antibodies. Organs and systems that may be affected include the skin, gastrointestinal tract, liver, lungs, endocrine glands, neurological system, and blood cells. These immune-related toxicities can emerge prior to, during, or post monoclonal antibody-based therapy, varying in persistence and response to immunosuppressive interventions.

COVID-19 Impact on Global Monoclonal Antibody-Based Prostate Cancer Immunotherapy Market:

The COVID-19 pandemic has wielded both favorable and adverse effects on the monoclonal antibody-based market for prostate cancer. Notably, the pandemic has spurred research and development interest in monoclonal antibodies for various diseases, including COVID-19. Some monoclonal antibody-based drugs authorized or under investigation for COVID-19, such as basiliximab, imdevimab, and sotrovimab, hold potential for applications in prostate cancer treatment due to their targeting of immune checkpoint molecules relevant to viral and tumor immune evasion. This heightened awareness among patients and healthcare professionals could potentially boost the demand for monoclonal antibody-based treatments in prostate cancer. However, the COVID-19 pandemic has also posed challenges for the monoclonal antibody-based market in prostate cancer. Disruptions in the production process and supply chain for monoclonal antibodies have resulted in shortages and delays in certain regions. Additionally, the pandemic has impacted the recruitment and conduct of clinical trials for monoclonal antibody-based prostate cancer therapies, slowing progress and potentially affecting data quality. The increased financial and emotional strain on prostate cancer patients due to the pandemic may also hinder their access to and adherence to monoclonal antibody-based therapies.

Global Monoclonal Antibody-Based Prostate Cancer Immunotherapy Market Recent Developments:

December 2021:

The U.S. FDA approved lutetium-177-PSMA-617 (Lutathera), a radiolabeled anti-PSMA monoclonal antibody, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) that has progressed following prior treatment with at least one androgen receptor-directed therapy and one taxane-based chemotherapy.

May 2021:

Dostarlimab (Jemperli), an anti-PD-1 monoclonal antibody, received accelerated approval from the U.S. FDA for the treatment of recurrent or advanced endometrial cancer that has progressed during or after prior treatment with platinum-containing chemotherapy, and whose tumors exhibit a mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H).

Global Monoclonal Antibody-Based Prostate Cancer Immunotherapy Market Segmentation: By Product Type

• Anti- Prostate Specific Membrane Antigen (PSMA) Monoclonal Antibody-Based
• Anti- Cytotoxic T-Lymphocyte Associated Antigen 4 (CTLA-4) Monoclonal Antibody-Based
• Anti-Programmed Cell Death Protein 1 PD-1/ligand PD-L1(PD-1/PD-L1) Monoclonal Antibody-Based
• Others

The Anti-Prostate Specific Membrane Antigen (PSMA) Monoclonal Antibody-Based category is a leading segment within the market. PSMA, a protein prominently expressed on prostate cancer cell surfaces, presents an attractive target for immunotherapy. Monoclonal antibodies designed to target PSMA enable precise targeting of prostate cancer cells. These antibodies can be employed to deliver therapeutic agents or to activate the immune system against cancer cells. The prevalence of PSMA as a focal point in prostate cancer immunotherapy research and the escalating number of clinical investigations on PSMA-targeted monoclonal antibodies contribute to the dominance of this market segment.

The Anti-Programmed Cell Death Protein 1 PD-1/ligand PD-L1 (PD-1/PD-L1) Monoclonal Antibody-Based sector represents the fastest-growing segment. This growth is propelled by the favorable outcomes exhibited by PD-1/PD-L1 inhibitors in the treatment of various malignancies, including prostate cancer. These inhibitors function by obstructing the interaction between PD-1, a protein present in immune cells, and PD-L1, a protein found in cancer cells. Consequently, the immune system becomes more adept at recognizing and combating cancer cells. The utilization of PD-1/PD-L1 inhibitors in prostate cancer immunotherapy continues to drive the expansion of this market.

The Global Monoclonal Antibody-Based Prostate Cancer Immunotherapy Market Segmentation: By Application

• Early-Stage prostate cancer
• Metastatic prostate cancer
• Castration-resistant prostate cancer

Metastatic prostate cancer, characterized by the spread of prostate cancer to other areas of the body such as the bones, lymph nodes, liver, or lungs, is poised to experience the most rapid growth within the market. This projection is founded on the increasing incidence and mortality rates of metastatic prostate cancer, the limited efficacy and survival advantages of conventional treatments, and the introduction of new monoclonal antibodies (mAbs) capable of targeting metastatic lesions, thereby enhancing clinical outcomes. Examples of mAbs for metastatic prostate cancer include lutetium-177-PSMA-617, pembrolizumab, nivolumab, atezolizumab, and enoblituzumab.

Castration-resistant prostate cancer (CRPC), denoting prostate cancer that progresses despite reduced testosterone levels due to hormonal therapy, is anticipated to dominate the market segmentation by application. The high prevalence and poor prognosis associated with CRPC, the availability of approved mAbs tailored for CRPC, and the considerable demand and acceptance of mAbs for CRPC contribute to this sector's substantial market share. Notable examples of mAbs for CRPC include Sipuleucel-T, ipilimumab, pembrolizumab, nivolumab, atezolizumab, and enoblituzumab.

Global Monoclonal Antibody-Based Prostate Cancer Immunotherapy Market Segmentation: By Distribution Channels

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

Online pharmacies, platforms offering mAbs for prostate cancer immunotherapy directly to consumers through e-commerce, are forecasted to exhibit the most significant growth within the market. The projected expansion is attributed to the increasing adoption and penetration of e-commerce, rising demand for home delivery services, availability of discounts and promotions, and the convenience and privacy afforded by online pharmacy platforms. This market segment is expected to grow at a notable CAGR.

Hospital pharmacies, located within or in close proximity to hospitals, where mAbs for prostate cancer immunotherapy are dispensed to patients or healthcare providers, are predicted to be the most prevalent category in the distribution channel segmentation. The extensive prescription and consumption rates of mAbs for prostate cancer immunotherapy in hospital settings, the presence of trained and qualified pharmacists, adherence to quality and safety standards, and the support of reimbursement policies and government initiatives for hospital pharmacies contribute to the anticipated substantial market share of this segment.

Global Monoclonal Antibody-Based Prostate Cancer Immunotherapy Market Segmentation: By End User

• Hospitals and clinics
• Cancer research centers
• Academic and research institutes

Hospitals and clinics, healthcare institutions offering diagnosis, treatment, and care for prostate cancer patients using mAbs for immunotherapy, are expected to represent the most prevalent sector in the market segmentation by end-user. The widespread prescription and usage of mAbs for prostate cancer immunotherapy in hospital and clinic settings, the availability of trained and qualified healthcare professionals, adherence to quality and safety standards, and the support of reimbursement policies and government initiatives for hospitals and clinics all contribute to the significant market share projected for this segment.

Academic and research institutions, organizations engaged in research and education concerning various aspects of mAbs for prostate cancer immunotherapy, such as discovery, development, testing, and evaluation, are anticipated to experience the fastest rate of expansion within the market segment. This growth is fueled by increasing funding and backing for monoclonal antibody-based research from diverse sources including governmental bodies, non-governmental organizations, industry partners, and philanthropic donors. Examples of such institutions involved in monoclonal antibody-based research include Stanford University, University of California San Francisco, Johns Hopkins University, National Cancer Institute, Cancer Research UK, and the Parker Institute for Cancer Immunotherapy.

Global Monoclonal Antibody-Based Prostate Cancer Immunotherapy Market Segmentation: By Region

• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

North America is forecasted to emerge as a highly lucrative market for cancer immunotherapy during the projection period. The market in this region is primarily driven by a well-established healthcare infrastructure and increasing government initiatives. Factors such as the rising number of cancer cases, heightened utilization of immunotherapy, and the development of bioinformatics tools facilitating drug development processes contribute to North America's substantial market share. Conversely, the market in the Asia Pacific region is projected to experience the swiftest growth during the forecasted period. Countries such as China and Japan have introduced novel and advanced immunotherapy medications. Approval of several novel drug compounds and combination therapies by the FDA in these nations, along with numerous ongoing clinical trials, contribute to the expanding use of immunotherapy for tumor treatment in China and Japan.

Key Players:

1. Amgen, Inc.,
2. NOVARTIS AG,
3. GlaxoSmithKline plc,
4. ELI LILY AND COMPANY,
5. Pfizer, Inc.,
6. BAYER AG
7. Merck & Co
8. Janssen Biotech
9. Bristol-Myers Squibb Company,
10. Spectrum Pharmaceuticals